TD Cowen raised its share-price target for AVITA and kept its buy rating. This is a more favorable view of the shares, though the story reports no change in sales or profit.
That gives investors a more favorable outside view of AVITA's shares. It does not show that the company's sales or profit changed, so the support comes from the analyst's opinion alone.
Follow AVITA Medical, Inc. (RCEL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCEL